Background/Methods:
- Leptomeningeal disease (LMD) is a challenging complication of high grade glioma (HGG) and questions remain regarding risk factors, molecular associations, and optimal treatment. Here we report updated results on a larger cohort from our previously reported multicenter study (Shoaf et al. 2022, NeuroOncology [Abstract]).
- Patients with molecularly-profiled HGG (Caris Life Sciences; Phoenix, AZ) with LMD at 3 institutions were included. Medical records were reviewed for clinicopathologic characteristics and outcome, and Next Generation Sequencing was performed.